反应详情

The compound was prepared in an analogous manner as described for intermediate B14A from (R)-5-(5-amino-2-fluorophenyl)-6,6-difluoro-5,7,7-trimethyl-[1,4]oxazepane-3-thione (intermediate A17B) (150 mg, 0.47 mmol) and commercially available 5-chloro-pyridine-2-carboxylic acid [CAS No. 86873-60-1] (111 mg, 0.71 mmol). The compound was obtained as a yellow foam (330 mg, 99%, 65% purity). MS (ISP): m/z=460.4 [(M+H)+] and 462.1 [(M+2+H)+].

1. customThe compound was prepared in an analogous manner
2. customThe compound was obtained as a yellow foam (330 mg, 99%, 65% purity)